4
ALL4
Allena PharmaceuticalsYear
4
ALL3
20211
2020DEALS // DEV.
4
ALL1
Deals3
DevelopmentsCountry
4
ALL4
U.S.A4
ALL1
H.C. Wainwright & Co3
InapplicableTherapeutic Area
4
ALL1
Gastroenterology1
Nephrology2
RheumatologyStudy Phase
4
ALL2
Phase III2
Phase IIDeal Type
4
ALL3
Inapplicable1
Public OfferingProduct Type
4
ALL4
EnzymeDosage Form
4
ALL4
Oral CapsuleLead Product
4
ALL2
Engineered Urate Oxidase2
ReloxaliaseTarget
4
ALL2
Undisclosed2
UrateLead Product(s) : Engineered Urate Oxidase
Therapeutic Area : Rheumatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
Details : Allena recently completed a Phase 1b multiple ascending dose study of ALLN-346. The study included 18 healthy volunteers, who received either ALLN-346 or placebo (2:1 randomization) for seven days.
Product Name : ALLN-346
Product Type : Enzyme
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Engineered Urate Oxidase
Therapeutic Area : Rheumatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Reloxaliase
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $28.0 million
Deal Type : Public Offering
Details : Allena’s lead product candidate, reloxaliase (formerly ALLN-177), is a first-in-class, non-absorbed, orally-administered enzyme for the treatment of hyperoxaluria.
Product Name : ALLN-177
Product Type : Enzyme
Upfront Cash : Undisclosed
July 14, 2021
Lead Product(s) : Reloxaliase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $28.0 million
Deal Type : Public Offering
Lead Product(s) : Engineered Urate Oxidase
Therapeutic Area : Rheumatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company is developing ALLN-346 for the treatment of hyperuricemia and gout in the setting of advanced CKD, with a Phase 1 multiple ascending dose study recently completed and a Phase 2a program underway.
Product Name : ALLN-346
Product Type : Enzyme
Upfront Cash : Inapplicable
March 11, 2021
Lead Product(s) : Engineered Urate Oxidase
Therapeutic Area : Rheumatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Reloxaliase
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2
Details : Allena now plans to reducing target enrollment to 200 subjects. Conducting earlier interim analysis, expected in Q3 2021.
Product Name : ALLN-177
Product Type : Enzyme
Upfront Cash : Inapplicable
December 02, 2020
Lead Product(s) : Reloxaliase
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable